Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - neoplażmi tas-sider - aġenti antineoplastiċi - ibrance huwa indikat għall-kura ta 'l-ormon tat-riċettur (hr) pożittiv, tal-bniedem tar-riċettur tal-fattur tat-tkabbir epidermali 2 (her2) negattivi lokalment avvanzata jew metastatika tal-kanċer tas-sider:f'kumbinazzjoni ma' inibitur aromatase;flimkien ma ' fulvestrant f'nisa li kienu rċevew qabel terapija endokrinali. fil - pre- jew perimenopausal-nisa, l-endokrinali it-terapija għandha tingħata flimkien ma ' ormon luteinizing releasing hormone (lhrh) agonist.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited  - metaflumizone - ektoparasitaċidali għall-użu topiku, inklużi. insettiċidi - qtates - trattament u prevenzjoni ta 'infestazzjonijiet tal-briegħed (ctenocephalides canis u c. felis) fil-qtates. il-prodott mediċinali veterinarju jista 'jintuża bħala parti minn strateġija ta' trattament għal dermatite tal-allerġija tal-briegħed (fad).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited  - metaflumizone, amitraz - ektoparasitaċidali għall-użu topiku, inklużi. insettiċidi - klieb - għat-trattament u l-prevenzjoni ta 'infestazzjonijiet bil-briegħed (ctenocephalides canis u c. felis) u qurdien (ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus u dermacentor variabilis), u għall-kura ta ' demodikosi (ikkawżata minn demodex spp. ) u qamel (trichodectes canis) fil-klieb. il-prodott mediċinali veterinarju jista 'jintuża bħala parti minn strateġija ta' trattament għal dermatite tal-allerġija tal-briegħed (fad).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - aġenti antineoplastiċi - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - neoplażmi tas-sider - aġenti antineoplastiċi - talzenna huwa indikat bħala monoterapija għall-kura ta ' pazjenti adulti bil-linja ġerminali brca1/2 mutazzjonijiet, li għandhom her2-negattivi avvanzat lokalment jew metastatiku tas-sider kanċer. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. pazjenti bl-ormon tat-riċettur (hr)-kanċer tas-sider posittiv għandhom kienu ttrattati minn qabel endokrinali bbażata fuq it-terapija, jew jiġu kkunsidrati bħala mhux tajbin għall-endokrinali-terapija bbażata fuq.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohydrate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - vizimpro, bħala monoterapija, huwa indikat għall-kura tal-ewwel linja ta 'pazjenti adulti b'lokalment avvanzat jew dak metastatiku li mhux ta' ċelluli żgħar kanċer tal-pulmun (nsclc) mar-riċettur tal-fattur tat-tkabbir epidermali (egfr) mutazzjonijiet li jattivaw.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosoppressanti - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.